DDInter1042 DDInter1506
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Pramlintide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Corticotropin
Pramlintide {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Pramlintide may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Pramlintide may lead to a major life threatening interaction when taken with Gatifloxacin